Diffusion Pharmaceuticals Inc. announced that Raven Jaeger, M.S., has joined the Company as its Chief Regulatory Officer effective immediately. Ms. Jaeger will be responsible for development and implementation of regulatory and related strategies to support the development and commercialization of Diffusion's product development candidates, including the Company's lead candidate, trans sodium crocetinate (TSC), which is planned for development as an adjunct to standard of care therapy for hypoxic solid tumors. Ms. Jaeger joins Diffusion from BridgeBio Pharma Inc. where she was most recently Senior Vice President, Regulatory Affairs.

During her time there, she successfully built and led a regulatory affairs team responsible for global regulatory strategy and operations for multiple development programs within several affiliate companies, whereby she led her team to gaining the first US FDA regulatory approval for the company.